New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris
Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs
Test delivers results in just 18 minutes, enabling faster laboratory workflows and patient management during outbreaks
Quest Diagnostics’ blood-based test panels demonstrate confirmatory accuracy, potentially reducing the need for PET imaging
Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
OS is a key secondary endpoint of the 948-patient study, which is evaluating whether adding AstraZeneca's PD-L1 inhibitor to standard FLOT chemotherapy
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
Yesintek and Yesintek I.V. are approved for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients
The submissions are supported by data from the Phase 3 KEYNOTE-905 trial
Subscribe To Our Newsletter & Stay Updated
